Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Glioblastoma 12Central Nervous System Neoplasms 11Brain Neoplasms 9Astrocytoma 8Glioma 6Oligodendroglioma 4Gliosarcoma 3Neoplasms 2Medulloblastoma 2Leukemia, Myeloid, Acute 2Spinal Cord Neoplasms 1Optic Nerve Glioma 1Neoplasms, Plasma Cell 1Neoplasm Recurrence, Local 1Multiple Myeloma 1Cognition Disorders 1

Interventions

Dexamethasone 168Bortezomib 90Lenalidomide 85Thalidomide 44daratumumab 43pomalidomide 42Melphalan 39Cyclophosphamide 33carfilzomib 29Calcium Dobesilate 27Prednisone 19Doxorubicin 16elotuzumab 14Filgrastim 12ixazomib 11isatuximab 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10belantamab mafodotin 9Granulocyte Colony-Stimulating Factor 9Zoledronic Acid 8selinexor 7dexamethasone acetate 7Epoetin Alfa 7Etoposide 6fludarabine 5Cisplatin 5Carmustine 5Radiotherapy 4Mycophenolic Acid 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Multiple Myeloma × Lomustine × Clear all
NCT00003603 2013-09-20

Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Unknown
660 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡